Argatroban has been approved in the United States

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


argatroban studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
SKF105043/013 IV An Open-Label Study of Argatroban Injection to Evaluate the Safety and Effectiveness in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
ARG-402 II Pharmacokinetics and Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease (ESRD) Patients Undergoing Hemodialysis
SKF 105043 011 II An Open-label, Multicenter, Adaptive Design, Pilot Trial to Examine the Safety and Effectiveness of Argatroban in Combination with Abciximab, a Platelet GP IIb/IIIa Receptor Antagonist in Patients Undergoing Non-urgent Percutaneous Coronary Intervention
SKF 105043 011 (Part 2) II An Open-label, Multicenter, Adaptive Design, Pilot Trial to Examine the Safety and Effectiveness of Argatroban in Combination with Abciximab, a Platelet GP IIb/IIIa Receptor Antagonist in Patients Undergoing Non-urgent Percutaneous Coronary Intervention (Part 2)